GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Return-on-Tangible-Asset

FluoroPharma Medical (FluoroPharma Medical) Return-on-Tangible-Asset : -664.05% (As of Dec. 2016)


View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. FluoroPharma Medical's annualized Net Income for the quarter that ended in Dec. 2016 was $-0.51 Mil. FluoroPharma Medical's average total tangible assets for the quarter that ended in Dec. 2016 was $0.08 Mil. Therefore, FluoroPharma Medical's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2016 was -664.05%.

The historical rank and industry rank for FluoroPharma Medical's Return-on-Tangible-Asset or its related term are showing as below:

FPMI's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -40.005
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

FluoroPharma Medical Return-on-Tangible-Asset Historical Data

The historical data trend for FluoroPharma Medical's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical Return-on-Tangible-Asset Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -159.28 -327.32 -354.74 -644.40 -713.04

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -452.34 -1,883.83 -944.05 537.06 -664.05

Competitive Comparison of FluoroPharma Medical's Return-on-Tangible-Asset

For the Biotechnology subindustry, FluoroPharma Medical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FluoroPharma Medical's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Return-on-Tangible-Asset falls into.



FluoroPharma Medical Return-on-Tangible-Asset Calculation

FluoroPharma Medical's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2016 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=-2.05/( (0.52+0.055)/ 2 )
=-2.05/0.2875
=-713.04 %

FluoroPharma Medical's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2016 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2016 )  (Q: Sep. 2016 )(Q: Dec. 2016 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2016 )  (Q: Sep. 2016 )(Q: Dec. 2016 )
=-0.508/( (0.098+0.055)/ 2 )
=-0.508/0.0765
=-664.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2016) net income data.


FluoroPharma Medical  (OTCPK:FPMI) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


FluoroPharma Medical Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


FluoroPharma Medical (FluoroPharma Medical) Business Description

Traded in Other Exchanges
N/A
Address
8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042
FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.
Executives
Johan M. Spoor director, officer: CEO, PRESIDENT, CHAIRMAN 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus